BLOG

FDA clears IND application for off-the-shelf, BCMA-directed CAR-T for advanced myeloma

The FDA cleared an investigational new drug application for CYAD-211, a chimeric antigen receptor T-cell therapy for the treatment of relapsed or refractory multiple myeloma, according to a press release from the agent’s manufacturer.